SCHEMBL1644995

SCHEMBL1644995

Cc1ccc2nc(-c3ccc(F)cc3)[nH]c(=O)c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 12/20 0.66
TNKS2 Q9H2K2 12/20 0.66
PARP1 P09874 9/20 0.66
PARP2 Q9UGN5 3/20 0.65
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 1/20 0.49
NR4A2 P43354 1/20 0.49
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11079397 0.91 TNKS (0.72) TNKSTNKS2PARP1PARP2NPC1
Morpholine SCHEMBL27920479 0.88 TNKS (0.54) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL11826929 0.87 TNKS (0.70) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL11077586 0.86 TNKS (0.65) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL11083849 0.86 TNKS (0.65) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL27760624 0.83 TNKS (0.67) TNKSTNKS2PARP1PARP2NR4A2
SCHEMBL17786424 0.83 TNKS (0.65) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL259245 0.81 TNKS (0.71) TNKSTNKS2PARP1PARP2NPC1
SCHEMBL11376165 0.81 NR4A2 (0.71) TNKSTNKS2PARP1PARP2NR4A2
SCHEMBL8270073 0.80 TNKS (0.70) TNKSTNKS2PARP1PARP2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104557738-A Green synthesis method of 4(3H)-quinazolinone UNIV HUNAN 2015-04-29 CN disclosed
EP-2314295-B1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX INC (CA) 2015-01-28 EP disclosed
US-8410109-B2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX CORP. (CA) 2013-04-02 US disclosed
EP-2314295-A1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices Resverlogix, Inc (CA) 2011-04-27 EP disclosed
CN-101365446-A Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery via implantable medical devices RESVERLOGIX CORP (CA) 2009-02-11 CN disclosed
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US disclosed
EP-1909788-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2008-04-16 EP disclosed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices VCAM1, ICAM1, TGFB1 TNKS 2747/4885TNKS2 3811/4885PARP1 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.